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Background: The prevalence of obesity is increasing worldwide and significantly affects fertility and reproduction in
both men and women. Our recent study has shown that excess body fat accelerates ovarian follicle development and
follicle loss in rats. The aim of the present study is to explore the effect of SIRT1 activator SRT1720 on the reserve of
ovarian follicle pool and ovarian lifespan of obese mice and the underlying mechanism associated with SIRT1 and
mTOR signaling.
Methods: Adult female Kunming mice (n = 36) were randomly divided into three groups: the normal control (NC)
group (n = 8), the caloric restriction (CR) group (fed 70% food of the NC group, n = 8) and the high-fat diet (HF) group
(fed a rodent chow containing 20% fat, n = 20). After 4 months, the HF mice were further randomly divided into three
groups: the control high-fat diet (CHF, n = 8) group (treated every day with an intraperitoneal injection of vehicle), the
SRT1720 (SRT, n = 6) group (treated every other day with an intraperitoneal injection of SRT1720 (50 mg/kg)), the
SRT1720 and nicotinamide (NAM, n = 6) group (treated every other day with an intraperitoneal injection of SRT1720
(50 mg/kg) and every day with an intraperitoneal injection of nicotinamide (100 mg/kg)). After 6 weeks of treatment,
ovaries were harvested for histological and Western blotting analyses.
Results: The body weight, ovary weight and visceral fat in the SRT group were significantly lower than those in the
CHF group at the end of treatment. Histological analysis showed that the SRT mice had significantly greater number
and percentage of primordial follicles, but lower number and percentage of corpora lutea and atretic follicles than the
CHF mice and NAM mice. Western blot analysis demonstrated that the levels of SIRT1, SIRT6, FOXO3a and NRF-1 protein
expression significantly increased in the ovaries of SRT mice, whereas those of mTORC1, p-mTOR, p-p70S6K, NFκB and
p53 decreased compared to the CHF and NAM mice.
Conclusions: Our study suggests that SRT1720 may improve the follicle pool reserve in HF diet-induced obese female
mice via activating SIRT1 signaling and suppressing mTOR signaling, thus extending the ovarian lifespan.
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The prevalence of obesity has steadily increased over the
past three decades all over the world, and newly released
data has showed that nearly one-third of the world’s
population is obese or overweight [1]. Significant evi-
dence suggests that excess body fat is a major risk factor
for non-insulin-dependent diabetes mellitus, cardiovas-
cular diseases, cancers, gastrointestinal diseases, arthritis
and metabolic disorders [2], as well as disruptions in
reproduction [3]. Excess body fat (particularly abdominal
obesity) is closely related to irregular menstrual cycles,
reduced spontaneous conception and increased risk of
miscarriage [4,5]. A recent study indicated that obesity
negatively impacted oocyte and embryo quality [6]. In
parallel to findings in human beings, diet-induced obese
mouse studies have shown a wide range of negative re-
productive phenotypes in addition to poor outcomes in
the offspring from these mice [7-9]. Additionally, our
previous study demonstrated that obesity accelerated
ovarian follicle development and follicle loss in female
rats [10]. Female fertility is determined by the size of the
primordial follicle pool formed during fetal life and by
the rate of depletion of the pool after birth [11]. In
addition to reduced ovarian complement, early deple-
tion of the follicular pool due to excess follicular acti-
vation and/or atresia can occur and results in infertility
[12,13]. Childhood obesity also has a negative effect on
reproduction, which may lead to early onset of puberty,
menstrual irregularities during adolescence and polycys-
tic ovary syndrome [14]. These studies shed light on the
negative effects of obesity on the reproductive functions
in females. However, how obesity affects the ovarian fol-
licle development, and the underlying mechanisms re-
main elusive.
Anti-obesity management can improve cardiovascular
and diabetes risk factors in overweight and obese indi-
viduals [15], as well as reproduction disease [16]. Resver-
atrol, a natural SIRT1 activator, can partly mimic effects
of calorie restriction (CR) in mice and obese humans
[17,18]. Resveratrol has anti-aging effect and also benefi-
cial effects of cardiovascular and metabolic system [19,20].
Consistently, it prolongs the ovarian lifespan and protects
against age-associated infertility in rodents [21,22]. How-
ever, resveratrol is not a specific activator of SIRT1, and it
can also activate other signaling pathways [23]. SRT1720,
a specific activator of SIRT1, is 1000 times more potent
than resveratrol [24,25]. However, whether SRT1720 could
affect ovarian follicle development and promote the fol-
licle pool reserve through activating SIRT1 signaling is
unknown. In the present study, we used a high-fat diet
induced obese mouse model to characterize the effect of
SRT1720 on ovarian follicle development in adult obese
animals and to investigate the associated mechanism with
SIRT1 and mTOR signaling.Materials and methods
Materials
Primary and secondary antibodies applied in this study
were introduced as follows: SIRT1, FOXO3a, NRF-1,
mTOR, phospho-mTOR, phospho-p70S6 kinase α, NF-κB
and p53 antibodies were obtained from Santa Cruz
Biotechnology, USA; SIRT6 antibody was purchased from
Abcam, UK; β-actin was obtained from Zhongshan Golden
Bridge, Beijing, China; Secondary antibodies to mouse and
rabbit IgG were purchased from Sigma, USA. SRT1720
was obtained from Selleck, USA, and nicotinamide was ob-
tained from Sigma, USA. They were dissolved in double
distilled water containing 10% ethanol and 40% polyethyl-
ene glycol 400 for intraperitoneal injection [25].
Animals and regiments
Thirty six female Kunming mice (4 weeks old, 20 ± 2 g)
were purchased from Shantou University Medical College
Laboratory Animal Center. After 4 weeks of adaptation,
mice were randomly divided into three diet groups: the
normal control (NC) group (n = 8) fed ad libitum a stand-
ard rodent chow (4.84% fat,7.34% fiber, 20.11% protein,
plus all necessary vitamins and minerals, GE =3.5 Kcal/g),
the high-fat (HF) group (n = 20) fed ad libitum a high-fat
chow purchased from Shanghai Laboratory Animal Center
(20.0% fat, 21.0% protein, 43.5% carbohydrate, plus all ne-
cessary vitamins and minerals, GE =4.383 kcal/g), and the
CR group (n = 8) fed 70% of the food intake from the NC
group. We recorded daily food intake of the NC mice, and
the food supply of the CR group was adjusted accordingly.
After 4 months of high-fat diet treatment, the HF mice
were further randomly divided into three groups: the con-
trol high-fat diet (CHF) group (n = 8) (treated every day
with an intraperitoneal injection of vehicle), the SRT1720
(SRT) group (n = 6) (treated every other day with an intra-
peritoneal injection of SRT1720 (50 mg/kg)), the nicotina-
mide and SRT1720 (NAM) group (n = 6) (treated every
other day with an intraperitoneal injection of SRT1720
(50 mg/kg) and every day with an intraperitoneal injection
of nicotinamide (100 mg/kg) ). They were maintained on
these treatments for 6 weeks.
All of the mice were housed 2 in steel cages in a room
with an ambient temperature of 22°C ±2°C and a 12-hour
light:12-hour dark cycle and had free access to tap water.
All animal protocols were approved by the Institutional
Animal Care and Use Committee of Shantou University
Medical College.
Estrous cycle analysis
Vaginal smears of all mice were taken daily between 9:00
and 10:00 A.M. Vaginal cells were collected via a sterile
cotton swab moistened with normal saline, and then
placed on a clean glass slide. Stages were analyzed under
the microscope and assessed based on vaginal cytology
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regular cycle, and a cycle duration of >5 days or <4 days
was considered to be an irregular cycle [27].
Preparation of ovarian sections
The mice were weighed every four weeks. After 24 weeks,
mice were anaesthetized at the diestrus phase of the cycle
with pentobarbital sodium at 40 mg/kg body weight, and
sacrificed by cervical dislocation. Mouse perirenal fat was
isolated and weighed and expressed as visceral fat index.
Both ovaries of each mouse were removed and weighed.
One ovary was stored at −80°C for Western blot analysis,
and the other one was fixed in 4% paraformaldehyde at
room temperature for 4 hours, flushed under running
water for 3 hours, then dehydrated through a series of con-
centrations of ethanol, cleared in xylene and embedded in
paraffin. Ovarian sections of 4 μm were prepared for
hematoxylin and eosin (HE) staining.
HE staining and follicle classification
The sections were deparaffinized in xylene, hydrated
with decreasing alcohol concentrations, and stained with
HE using standard protocols. Sections were mounted
using Canada balsam and observed under a light micro-
scope. Five representative sections from each ovary were
selected for follicle counting, with each observed section
separated by a distance of over 80 μm. Follicles were
classified according to a previous study [28] as follows:
primordial follicle (an oocyte surrounded by one layer of
flattened granulosa cells), primary follicle (an oocyte sur-
rounded by one layer of cuboidal granulosa cells), sec-
ondary follicle (two or three layers of cuboidal granulosa
cells with no antral space), and antral follicle (more than
four layers of granulosa cells with one or more inde-
pendent antral spaces). In some cases, antral follicles
had no antral space in cross-section analysis, but were
considered antral if they contained more than five gran-
ulosa cell layers. Follicles were defined as either healthy
(intact germinal vesicle and nucleolus, oocyte with no
more than three cytoplasmic vacuoles, intact basalla-
mina) or atretic (apoptotic). If antral follicles contained
at least twenty apoptotic granulosa cells (defined by the
apoptotic bodies in the granulosa cell layer), disorganized
granulosa cells, a fragmentation of the oocyte nucleus, or a
degenerating oocyte, they were considered atretic [29].
Western blot analysis
Mouse ovaries were homogenized in Radio-
Immunoprecipitation Assay (RIPA) and Phenylmethane-
sulfonyl fluoride (PMSF) with a Teflon-glass homogenizer
on ice. After centrifugation (12,000 rpm, 15 min at 4°C),
the supernatants were collected for protein analysis. Pro-
tein concentrations were determined by the BCA Protein
Assay Kit (Beyotime). The protein samples were separatedby SDS–PAGE and transferred onto nitrocellulose mem-
branes (BioTrace™ NT, USA). The membranes were
blocked in 5% nonfat dry milk in Tris-Buffered-Saline with
Tween 20 (TBST) for 1 hour and incubated with a primary
antibody against SIRT1 (1:200 dilution), FOXO3a (1:200
dilution), SIRT6 (1:500 dilution), NRF1 (1:400 dilution),
mTOR (1:200 dilution), phospho-mTOR (1:500 dilution),
phospho-p70S6 kinase α (1:500 dilution), NFκB (1:600 di-
lution), p53 (1:600 dilution) or β-actin (1:5000 dilution)
over-night at 4°C, followed by the incubation with a
horseradish peroxidase-conjugated anti-rabbit or anti-
mouse antibody (1:5000 dilution) at room temperature
for 1 hour. Bands were visualized with a chemilumines-
cence reagent (Thermo Fisher Scientific, USA). Band
intensities were analyzed using the Quantity One software
(Bio-Rad Laboratories Pty. Ltd.). β - actin was used as a
loading control.
Statistical analysis
All results are expressed as the means ± S.E.M and ana-
lyzed by the SPSS 17.0 software. A one-way ANOVA
was used to compare the data among groups. A P-value
less than 0.05 was considered as statistical significance
(P <0.05).
Results
All mice were alive at the end of 24-week treatment, and
no superficial abnormalities or tumors were found in the
abdomen and other parts of the body.
The overall status
The CHF mice displayed obese phenotype and showed
unwieldy. In contrast, CR mice were thin and appeared
increased physical activity; they were sensitive to food
and foraged actively. Both the SRT and NAM mice had a
similar body type to the CR mice after 6-week drug
administration.
Energy intake, body weight and visceral fat
The food intake of the NC mice remained constant
throughout the course of the study, averaging 4.8 ± 0.02 g/d
(standard chow, GE =16.8 ± 0.07 kcal). The intake of the
CR group was controlled at an average of 3.4 ± 0.02 g/d
(GE =11.8 ± 0.06 kcal). HF mice consumed 4.7 ± 0.04 g/d
(HF diet, GE =20.8 ± 0.17 kcal) before drug administration
(Figure 1A). The caloric consumption was higher in HF
group than in the NC group (P < 0.001). During SRT1720
treatment, the energy intake of the SRT group gradually
decreased in the first two weeks, and then increased in the
middle two weeks. However, it decreased again and finally
was similar to that of the CR group (12.1 ± 0.4 kcal/d vs.
11.1 ± 0.1 kcal/d, P > 0.05), lower than that of the NC
group (16.4 ± 0.2 kcal/d, P < 0.001) (Figure 1B). The cal-
oric intake of the NAM group decreased in the first
Figure 1 Changes of energy intake among groups. (A) Before drug administration. (B) During drug administration. Food intake was measured
every day and the values were represented as means ± S.E.M.
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ing weeks. At the end of the treatment, it was close to that
of the CHF group (20.1 ± 1.2 kcal/d vs. 22.6 ± 0.5 kcal/d,
P > 0.05), but higher than that of the NC group (P < 0.001)
(Figure 1B).
No difference was observed in the body weight of mice
among the NC, CR and HF groups before the dietary
treatment (P > 0.05). The body weight of the NC mice
increased during the 26-week experiment (35.3 ± 0.5 g vs.
40.7 ± 1.7 g, P < 0.01), while that of the CR mice decreased
slightly and remained relatively stable later (34.6 ± 0.7 g vs.
33.5 ± 1.6 g, P > 0.05). The body weight of the HF mice sig-
nificantly increased from 34.9 ± 0.3 g to 55.0 ± 1.0 g during
the four-month dietary treatment (P < 0.001) (Figure 2A)
and they had 34% greater body weight than the NC
mice, which were considered as moderate obesity
[30,31]. Both the SRT group and the NAM group dis-
played a body weight dropped during the drug administra-
tion (38.7 ± 1.9 g vs. 52.1 ± 1.2 g, P < 0.05; 38.7 ± 1.5 g vs.
50.0 ± 2.1 g, P < 0.05), which were similar to the body
weight of the CR group (P > 0.05) (Figure 2B). However,the body weight of the CHF group remained relatively
stable (56.6 ± 2.1 g vs. 54.7 ± 3.4 g, P > 0.05) (Figure 3).
At the end of experiment, the perirenal fat pads were
isolated and weighed as the visceral fat. The CHF mice
had more visceral fat than the NC mice, while the vis-
ceral fat was less in the CR mice than in the NC mice.
The SRT and NAM mice had similar visceral fat to the
NC mice (Table 1).
The ovary weight
Both the CHF mice and the NAM mice had heavier
ovaries and higher ratio of ovary weight to body weight
than those of the NC mice. However, the gross ovary
weight and ovary ratio of the SRT group were similar to
those of the CR group, but less than those of the NC
group (Table 1).
Effect of SRT1720 and nicotinamide treatment on
estrous cycles
The estrous cycles of all mice were examined before the
treatment and only one of them represented an irregularly
Figure 2 Changes of body weight among groups. (A) Before the drug administration. (B) During the drug administration. The values were
represented as means ± SEM.
Figure 3 Comparison of the shapes of mice between the
groups at the end of the experiment.
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ited a shortened estrous cycle or continuous estrus phase
since the 8th week of diet treatment. However, after
6-week SRT1720 administration, 50% (3/6) SRT mice
changed the continuous estrus phase to 3, 5 and 6 days,
respectively. All the NAM and CHF mice maintained
continuous estrus phase during the drug treatment. Dur-
ing the experiment, 87.5% (7/8) of the CR mice gradually
exhibited an extended estrous cycle due to a prolonged
diestrus phase and only one CR mouse kept a regularTable 1 Body weight, ovary weight and visceral fat in all








NC 40.7 ± 1.7 9.1 ± 0.8 0.022 0.25 ± 0.03
CR 33.5 ± 1.6* 5.9 ± 0.5* 0.018 0.11 ± 0.03*
CHF 56.3 ± 3.4*** 18.7 ± 0.3*** 0.032** 1.24 ± 0.20***
SRT 38.7 ± 1.9 5.9 ± 1.0* 0.015 0.32 ± 0.10
NAM 38.7 ± 1.5 11.7 ± 1.1 0.031* 0.33 ± 0.07
Data are means ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the
NC group.
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SRT mice represented regularly again at the end of the
study. Meanwhile, 75% (6/8) NC mice maintained regular
estrous cycles until the end (Table 2).
Effect of SRT1720 and nicotinamide treatment on ovarian
follicular reserve
Comparison of the healthy follicles and atretic follicles
among groups
HE staining results showed that mouse ovaries were
mainly consisted of healthy follicles (primordial, primary,
secondary and antral follicles), corpora lutea and atretic
follicles. The number of healthy follicles in the SRT1720
group was similar to that of the CR group (121.7 ± 12.6 vs.
125.4 ± 8.7, P > 0.05), but more than that of the NC, CHF
and NAM group (121.7 ± 12.6 vs. 100.4 ± 6.5, 96.6 ± 2.2
and 101.8 ± 10.3, P < 0.05, respectively). The number of
atretic follicles in the SRT1720 group was similar to
that of the NC group (23.2 ± 2.2 vs. 28.3 ± 1.6, P > 0.05),
but less than that of the CHF group and the NAM group
(23.2 ± 2.2 vs. 42.2 ± 2.4, 36.3 ± 2.3, P < 0.05), while the
number of atretic follicles in the CR group was less thanTable 2 Percentage of mice at different stages of the estrous
Age and estrous
cycle stage
NC (n = 8) CR (n = 8)
% %
2 months
Regular cycling 100 100
Irregular cycling 0 0
3 months
Regular cycling 100 75
Irregular cycling 0 25
4 months
Regular cycling 100 62.5
Irregular cycling 0 37.5
5 months
Regular cycling 66.7 12.5
Irregular cycling 33.3 87.5
6 months
Regular cycling 75 12.5
Irregular cycling 25 87.5
7 months
Regular cycling 75 37.5
Irregular cycling 25 62.5
8 months
Regular cycling 75 37.5
Irregular cycling 25 62.5
Note: The dietary treatment started at the beginning of 8 weeks (2 months) of age
administration started at the 26 weeks of age and lasted for 6 weeks.that of the NC group (16.9 ± 1.6 vs. 28.3 ± 1.6, P < 0.001)
(Figure 4).
Comparison of the number of follicles at different stages
among groups
The mean number and percentage of primordial follicles
in the SRT1720 group were more than those of the NC
group (21.5 ± 1.1 vs. 13.1 ± 1.1; 11.4% ±0.7% vs. 7.7% ±0.6%,
P < 0.001, respectively), while those of the CHF group and
the NAM group were less than those of the NC group
(6.8 ± 0.3, 9.5 ± 1.1 vs. 13.1 ± 1.1, P < 0.001, P < 0.05,
respectively; 2.7% ±0.1%, 4.5% ± 0.6% vs. 7.7% ± 0.6%,
P < 0.001, P < 0.01, respectively). Although the SRT1720
group had a similar mean number of primordial follicles
to the CR group (21.5 ± 1.1 vs. 25.6 ± 1.0, P > 0.05), it had
less percentage of primordial follicles than the CR group
(11.4% ±0.7% vs. 16.2% ±0.6%, P < 0.001). The mean
number and percentage of developing follicles (including
primary, secondary and antral follicles) were compar-
able among groups (P > 0.05). The number and per-
centage of corpora lutea in the SRT1720 group were
similar to those of the NC group (46.2 ± 4.3 vs. 40.5 ± 3.4;cycle among groups
















and stopped at the end of 32 weeks (8 months) of age. The drug
Figure 4 Comparison of the healthy follicles and atretic follicles among groups. Data were presented as mean ± S.E.M. *P < 0.05, **P < 0.01,
***P < 0.001 vs. the NC group.
Zhou et al. Journal of Ovarian Research 2014, 7:97 Page 7 of 12
http://www.ovarianresearch.com/content/7/1/9724.6% ±2.8% vs. 24.1% ±2.1%, P > 0.05, respectively), but
less than those of the CHF and NAM group (46.2 ± 4.3 vs.
92.1 ± 4.9, 72.3 ± 5.0, P < 0.001, respectively; 24.6% ±2.8%
vs. 37.0% ±1.8%, 34.6% ±4.4%; P < 0.01, respectively). The
CR group had less corpora lutea than the NC group
(17.9 ± 4.7 vs. 40.5 ± 3.4; 11.6% ±1.5% vs. 24.6% ±2.8%,
P < 0.01, respectively) (Figure 5).
Western blotting analysis
To examine the activities of SIRT1/FOXO3a/NRF1-
SIRT6, mTOR-p70S6K signaling, NFκB and p53 in the
ovaries after SRT1720 and nicotinamide treatment, the
protein expression of SIRT1, SIRT6, FOXO3a, NRF-1,
mTORC1, p-mTOR, p-p70S6K, NFκB and p53 was mea-
sured by Western blotting. The result demonstrated that
the level of SIRT1, SIRT6, FOXO3a and NRF-1 proteins
significantly increased in the ovaries of the SRT and CR
mice, whereas that of mTORC1, p-mTOR, p-p70S6K,
NF-κB and p53 decreased compared to the NC mice.
Contrarily, the CHF and NAM mice displayed a signifi-
cant increase of mTORC1, p-mTOR, p-p70S6K, NFκB
and p53, and a significant decrease of SIRT1, SIRT6,
FOXO3a and NRF-1 proteins compared to the NC and
SRT mice (Figure 6).
Discussion
The epidemic of obesity is now recognized as one of the
most important public health problems facing the world
today and its impact on fertility is significant. As the
prevalence of obesity is increasing, the number of
women in the reproductive age who are becoming over-
weight and obese has the same trend. Obesity impacts at
least 30% of reproductive aged women [32]. Weight-loss
programs can improve fertility, hormones, ovulation in
obese female [33]. CR is an effective way to lose weight
and useful for prolonging the ovarian lifespan. Weightloss provides many benefits, but changing eating behavior
and maintenance of ideal weight are difficult and hard to
achieve [34,35]. Therefore, greater efforts are being de-
voted to understanding the mechanisms of CR-mediated
regulation of ovarian follicle development so that it can
provide new insight into extending ovarian lifespan and
also into the potential therapeutic targets for obese
females.
High-fat diet induced obesity accelerated the ovarian
follicle development and rate of follicle loss
In the present study, our data showed that obesity was
effectively induced since adult (8 weeks old) in mice by
ad libitum feeding of a high fat diet, for the CHF mice
had greater body weight and visceral fat at the end of
the study. Moreover, the CHF mice had less number and
percentage of primordial follicles, and a greater number
of corpora lutea and atretic follicles, suggesting that the
high-fat diet induced obesity may accelerate the rate of
follicle loss at least in three ways: i) stimulating the acti-
vation of primordial follicles; ii) promoting the develop-
ment and maturity of ovarian follicles; iii) promoting
follicle apoptosis. These results were coincident with our
previous findings [10].
SIRT 1 signaling was involved in the regulation of ovarian
follicle development
Mammalian SIRT1, the ortholog of yeast Sir2, is a class III
histone deacetylase (HDAC) whose activation is dependent
on nicotinamide adenine dinucleotide in the nucleus
[36,37]. It not only deacetylates histones, but also has a
wide range of non-histone sustrates, such as the forkhead
box class O (FOXO) family, p53 and nuclear factor κB
(NFκB), etc. [38-40]. Accumulated evidence has revealed
that SIRT1 is crucial for caloric restriction-induced longev-
ity [41-43], and SIRT1 genetic variation is related to obesity
Figure 5 Comparison of ovarian follicles at each stage among groups. (A) The mean number of ovarian follicles at each stage among groups.
(B) Percentage of ovarian follicles at each stage among groups. Data were presented as mean ± S.E.M. *P< 0.05, **P< 0.01, ***P< 0.001 vs. the NC group.
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body energy balance. SIRT1 also plays a role in repro-
ductive biology. SIRT 1 transgenic mice showed pheno-
types resembling CR and displayed prolonged lifespan,
inhibited ovarian follicular development and delayed sex-
ual maturity [45], whereas both male and female sirt1-
null mice were barren [46-48]. FOXO3a is known as an
important substrate of SIRT1. Mice with deletion of
FOXO3a gene have been shown to have abnormal ovar-
ian follicular development with early degeneration of oo-
cytes, resulting in age-dependent infertility [49], whereas
sexual maturity was delayed and follicle development
was inhibited in oocyte specific FOXO3a transgenic mice
[50]. Our previous study demonstrated that CR improved
the follicle reserve and extended ovarian lifespan with in-
creasing expression of SIRT1 and SIRT6 [51]. On the
contrary, the level of SIRT1 and SIRT6 expression in the
ovaries decreased in obese rats [10]. Kim et al. recently
reported SIRT1 forms a complex with FOXO3a and NRF1
on the SIRT6 promoter to positively regulated expression
of SIRT6 [52]. Our study also suggested that SIRT1/
FOXO3a/NRF1- SIRT6 signaling may be involved in CR
extending ovarian lifespan mechanisms [10].Both SIRT 1 transgenosis and activators of SIRT 1 can
mimic CR effect. However, it has remained elusive
whether SIRT1 signaling plays a role in the development
of ovarian follicles. Thus, we used SRT1720, the specific
activator of SIRT1, to investigate its effect on the follicle
development of the high-fat diet induced obesity mice.
Our results showed that SRT1720 treatment caused
an increase in the number and percentage of primordial
follicles, which was comparable to CR treatment, suggest-
ing that SRT1720 may inhibit the activation of primordial
follicles like CR. Although the numbers of secondary and
antral follicles were not significantly affected, the number
and percentage of corpora lutea were decreased by the
SRT1720 and CR treatment, suggesting that SRT1720 and
CR may suppress follicle maturation. This may explain
that the SRT1720-treated and CR ovaries were smaller
than those of the control. Moreover, both the number and
percentage of atretic follicles were significantly decreased
by SRT1720, suggesting that SRT1720 may inhibit follicu-
lar atresia. Nicotinamide, a form of vitamin B3, is a prod-
uct of Sir2-catalyzed deacetylation [53]. It has been clearly
demonstrated that nicotinamide can inhibit Sir2 enzymes
and down-regulate the expression of SIRT1 [54]. In the
Figure 6 The protein levels of SIRT1, FOXO3a, NRF-1, SIRT6, mTORC1, p-mTOR, p-p70S6K, NFκB and P53 in mouse ovaries by Western
blot analysis. (A) Western blot results. (B) Quantitative analysis of data in A. β-actin was used as internal control. Data are expressed as means ± S.E.M.
*P < 0.05, **P< 0.01, ***P< 0.001 vs. the NC group.
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features to the SRT or CR mice, their ovary weight, total
number of follicles and mean number of follicles at differ-
ent stages were comparable to that of the NC and CHF
mice, suggesting that nicotinamide attenuated the effect of
SRT1720. These results also suggest that SIRT1 signaling
may play an important role in the mechanism of CR ex-
tending ovarian lifespan.
SRT1720 treatment extended estrous cycle
It has been established that female reproductive aging is
closely associated with a decreased ovarian follicle re-
serve and gradual loss in regular estrous cyclicity at mid-
dle age [55,56] Hence, we examined the status of estrous
cycle in all groups. We found that the CR mice gradually
displayed an extended estrous cycle due to a prolonged
diestrus phase, while most HF mice exhibited a short-
ened estrous cycle or continuous estrus phase before
drug treatment. After treated with SRT1720, 3 of the 6
SRT mice changed the continuous estrus phase to 3, 5
and 6 days, respectively. We supposed that the extendedestrous cycle of the CR and SRT mice resulted from in-
sufficient estrogen secreted by fewer mature follicles.
This is in agreement with our follicle count results.
SRT1720 treatment enhanced SIRT 1 signaling and
attenuated mTOR signaling
mTOR (mammalian target of rapamycin,also known as
Frap1 in mice and other mammals), a ubiquitous, evolu-
tionarily conserved serine/threonine kinase, acts as a
central regulator of eukaryotic growth and cell division
in response to nutrient and growth factor cues. mTOR
generates two distinct complexes: rapamycin sensitive
mTOR complex 1 (mTORC1) and rapamycin insensitive
mTORC2. Previous studies reported that mTORC1-
S6K1-rpS6 signaling may be involved in the activation of
mammalian primordial follicles [57-59] and was nega-
tively regulated by SIRT1 [60].
With mammalian models of CR in our studies, we
found that CR significantly enhanced the reserve of fol-
licle pool by suppressing the activation of primordial fol-
licles as well as decreased protein expression of mTOR
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S6K signaling [10]. Interestingly, our results of the
present study also showed that SRT1720 had similar ef-
fects with CR, in which SRT1720 not only enhanced the
reserve of follicle pool, but also down-regulated mTOR
signaling, suggesting that mTOR signaling may be nega-
tively regulated by SIRT1 signaling. We found, moreover,
in the present study that SRT1720 induced a decrease of
energy intake by ~33.4% (about 66.6% energy intake of
the CHF mice), meaning that the SRT1720-treated mice
were in a CR condition. Consistently, the body weight of
SRT1720-treated mice was significantly less than that of
the CHF mice, although they ate the same food as the
CHF mice. These data also suggest that the effect of CR
is realized through the activation of SIRT1. Taking to-
gether, we speculate that SRT1720 may enhance the re-
serve of follicle pool by directly up-regulating SIRT1
signaling and thus down-regulating mTOR expression.
SRT1720 treatment attenuated NFκB signaling
Physiological events within the ovary, including ovula-
tion and corpus luteum formation and regression, have
been described as controlled inflammatory events [61].It
is now established that obesity causes a state of chronic
low-grade inflammation. Compared to healthy lean indi-
viduals, overweight and obese individuals have higher
pro-inflammatory cytokines, such as nuclear factor κB
[62,63]. It may partly explain why the CHF mice had
more corpus lutea and a higher expression of NFκB.
NFκB is a downstream of SIRT1 and it activates several
other pro-inflammatory cytokines (IL-6, TNF-α, IL-1β)
[64]. A recent study reported that the specific SIRT1 ac-
tivator SRT1720 exerted anti-inflammatory effects [65].
Consistently, our present study also found that SRT1720-
treated mice, as well as the CR mice, displayed signifi-
cantly decreased level of NFκB compared to the CHF
mice, suggesting that SIRT1 may play an important role in
the anti-inflammatory effect of CR and further contribute
to ovarian follicle development.
SRT1720 treatment inhibited p53 protein expression
P53, a tumor suppressor gene regulated by SIRT1-
mediated deacetylation, is a positive regulator of apop-
tosis in its native form (wild-type). The expression of
p53 protein in the apoptotic granulosa cells of atretic
follicles suggests its possible role in atresia [66]. A study
also showed that p53 played an important role in the
regulation and selection of oocytes at checkpoints, such
that oocytes that would otherwise be lost may persist
when p53 was absent or reduced [67]. These data suggest
that p53 may be associated with follicle atresia. SIRT1 reg-
ulates p53 acetylation and p53-dependent apoptosis [68].
Therefore, we examined the effect of CR and SRT1720 on
p53 protein expression in the mouse ovary. The resultsshowed that both CR and SRT1720 could inhibit p53 pro-
tein expression in the ovaries, which was probably due to
the activation of SIRT1.
Conclusions
Our present study suggests that SRT1720 treatment may
promote the ovarian lifespan of HF diet-induced obesity
female mice by suppressing the activation of primordial
follicles, the follicle maturation and atresia via activating
SIRT1 signaling and suppressing mTOR signaling. It may
also reduce the inflammatory reaction via modulating
NFκB signaling. We believe that a better understanding of
the interrelationship between SIRT1 and mTOR signaling
will promote the development of new pharmacological in-
sights to treat metabolic diseases associated with obesity.
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